LAKE FOREST, Calif.,
April 29, 2015 /PRNewswire/
-- Cryoport, Inc. (OTCBB: CYRX) ("Company"), the leading
provider of advanced cryogenic logistics solutions for the life
sciences industry, serving markets including immunotherapies, stem
cells, cell lines, clinical research organizations, vaccine
manufacturers and reproductive medicine, today announced that the
Company is supporting NeoStem, Inc.'s (NASDAQ: NBS) Intus Study to
evaluate its lead cancer immunotherapy, NBS20, for the treatment of
metastatic melanoma.
NeoStem, a biopharmaceutical company, is developing an
autologous immunotherapy that uses a patient's own tumor cells to
maximize the immune system's ability to identify and eliminate the
cancer initiating cells that NeoStem believes are capable of
reconstituting and developing new tumors. The proposed
therapeutic combines a patient's own purified and irradiated cancer
cells with specialized immune cells, educating the immune cells to
destroy the cancer initiating cells from which tumors arise.
The Intus Study for the treatment of metastatic melanoma has
received Special Protocol Assessment and the program has received
Fast Track and Orphan Drug Designations from the US Food and Drug
Administration ("FDA").
Cryoport's best-in-class cryogenic logistics solution is
providing comprehensive support for NeoStem's Intus Study, which is
advancing to a Phase 3 trial. The Company is an important
partner to the NBS20 development program as it launches the
multi-center trial and provides access to enrolled patients to the
cryopreserved, cell-based therapy that could potentially treat the
rapid progression of the deadly cancer.
David J. Mazzo, Ph.D., Chief
Executive Officer of NeoStem, commented, "At NeoStem, we are
dedicated to preserving and enhancing human health through
the development of novel cell-based individualized therapies
like our lead Phase 3 program in immuno-oncology, the Intus Study,
targeting the treatment of late-stage melanoma. Cryoport plays an
important role in NBS20 development by supporting the Intus Study
with the cryopreserved delivery of NBS20 to our clinical sites in
the United States. They have been instrumental in
facilitating trial access to our patients and we welcome the
opportunity to further strengthen and expand our relationship with
the company as we require additional support."
Jerrell Shelton, Chief Executive
Officer of Cryoport, stated, "We are pleased to be able to support
NeoStem with their efforts in developing innovative cell-based
personalized therapies. Our validated cryogenic logistics
solutions will maintain the integrity of the Intus trial as it
advances through the regulatory pathway that has been set by the
FDA. We are actively supporting the distribution of NBS20 and
will eagerly continue to support NeoStem as it advances its
clinical trials."
About Cryoport, Inc.
Cryoport is the premier provider of cryogenic logistics
solutions to the life sciences industry through its purpose-built
proprietary packaging, information technology and specialized cold
chain logistics expertise. We provide leading edge logistics
solutions for biologic materials such as immunotherapies, stem
cells, CAR-T cells, and reproductive cells for clients worldwide
including points-of-care, CRO's, central laboratories,
pharmaceutical companies, contract manufacturers, and university
researchers. Our packaging is built around our proprietary Cryoport
Express® liquid nitrogen dry vapor shippers, which are validated to
maintain a constant -150°C temperature for a 10 day dynamic
shipment duration. Our information technology centers around our
Cryoportal™ Logistics Management Platform, which facilitates
management of the entire shipment process. Cryoport is the
preferred cryogenic logistics solutions partner to the world's
largest shipping companies controlling more than 85% of the world's
air shipments. For more information, visit www.cryoport.com.
To download Cryoport's investor relations app, which offers
access to SEC documents, press releases, videos, audiocasts and
more, please click to download from your iPhone and iPad
or Android mobile device.
Forward Looking Statements
Statements in this news release which are not purely
historical, including statements regarding Cryoport, Inc.'s
intentions, hopes, beliefs, expectations, representations,
projections, plans or predictions of the future are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. It is important to note that the company's
actual results could differ materially from those in any such
forward-looking statements. Factors that could cause actual results
to differ materially include, but are not limited to, risks and
uncertainties associated with the effect of changing economic
conditions, trends in the products markets, variations in the
company's cash flow, market acceptance risks, and technical
development risks. The company's business could be affected by a
number of other factors, including the risk factors listed from
time to time in the company's SEC reports including, but not
limited to, the annual report on Form 10-K for the year ended
March 31, 2013. The company cautions
investors not to place undue reliance on the forward-looking
statements contained in this press release. Cryoport, Inc.
disclaims any obligation, and does not undertake to update or
revise any forward-looking statements in this press
release.
Logo -
http://photos.prnewswire.com/prnh/20140401/NY95107LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cryoport-supports-neostems-intus-study-for-the-treatment-of-metastatic-melanoma-300073937.html
SOURCE Cryoport, Inc.